Arcadia Biosciences initiated with a Buy at National Securities. National Securities analyst Ben Klieve initiated Arcadia Biosciences with a Buy rating and $15 price target, telling investors in a research note that Arcadia is a small cap investment that is addressing a large scale market opportunity by utilizing gene technology to develop crops with enhanced nutritional profiles and growth characteristics. “A number of development initiatives” are starting to transition to commercialization, Klieve says, adding that he expects the company will move to a $100M revenue business in 2023 from a pre-commercial revenue business in 2018
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.